LONDON, April 17 (Reuters) - An experimental lung cancer pill from AstraZeneca delays disease progression by more than a year, according to new data presented at a medical meeting on Friday.
AZD9291, which the company expects to file for U.S. approval in the second quarter of 2015, is one of a number of cancer medicines AstraZeneca is hoping will rebuild its sales following patent losses on older drugs.
16:36 AT&T, Time Warner poised to lobby lawmakers, regulators on proposed $85-billion merger23
12:23 Lockheed Martin's quarterly profit handily beats estimates25
11:46 GM reports record 3Q earnings despite slowing US sales12
11:41 Caterpillar earnings: 85 cents per share, vs expected EPS of 76 cents20